Boston Scientific (BSX) Aperçu de l'action
Boston Scientific Corporation développe, fabrique et commercialise des dispositifs médicaux destinés à être utilisés dans diverses spécialités médicales interventionnelles dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 1/6 |
| Performances passées | 5/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
BSX Community Fair Values
Create NarrativeSee what 168 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$98.9
FV
50.4% sous-évalué décote intrinsèque9.80%
Revenue growth p.a.
709
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
23users have followed this narrative
Boston Scientific Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$49.09 |
| Plus haut sur 52 semaines | US$109.50 |
| Plus bas sur 52 semaines | US$42.20 |
| Bêta | 0.57 |
| Variation sur 1 mois | 8.75% |
| Variation sur 3 mois | -12.34% |
| Variation sur 1 an | -53.17% |
| Variation sur 3 ans | -2.95% |
| Variation sur 5 ans | 15.10% |
| Évolution depuis l'introduction en bourse | 1,046.63% |
Nouvelles et mises à jour récentes
Seeking Alpha • Jul 30
Boston Scientific: Attempting The 2027 Reset
Summary Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency. I expect achievable 2024 EPS at the high end of guidance ($3.32) and see potential for $3.69–$4.00 EPS in 2025 if operational improvements materialize. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 28
BSX: Long-Term Pipeline And Buybacks Will Counter Watchman Uncertainty
Boston Scientific's updated analyst price target of $72.25, compared with the prior $75.00 fair value estimate, reflects a broad wave of Street target cuts as analysts factor in softer Watchman and electrophysiology expectations, while still pointing to intact fundamentals and underappreciated growth areas. Analyst Commentary Recent Street research on Boston Scientific points to a reset in expectations around Watchman and electrophysiology, while still highlighting core strengths in the broader portfolio.Recent updates
Seeking Alpha • Jul 30
Boston Scientific: Attempting The 2027 Reset
Summary Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency. I expect achievable 2024 EPS at the high end of guidance ($3.32) and see potential for $3.69–$4.00 EPS in 2025 if operational improvements materialize. Read the full article on Seeking AlphaMise à jour du récit • Jul 28
BSX: Long-Term Pipeline And Buybacks Will Counter Watchman Uncertainty
Boston Scientific's updated analyst price target of $72.25, compared with the prior $75.00 fair value estimate, reflects a broad wave of Street target cuts as analysts factor in softer Watchman and electrophysiology expectations, while still pointing to intact fundamentals and underappreciated growth areas. Analyst Commentary Recent Street research on Boston Scientific points to a reset in expectations around Watchman and electrophysiology, while still highlighting core strengths in the broader portfolio.
Mise à jour du récit • Jul 14
BSX: Reset Growth Expectations Will Set Stage For Future Recovery Potential
Analyst price targets for Boston Scientific have been revised downward by roughly $25 to $30 as analysts factor in softer Watchman growth, ongoing electrophysiology headwinds, and slightly more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Boston Scientific points to a mixed but still constructive backdrop, with many firms trimming price targets while maintaining positive ratings.Mise à jour du récit • Jun 30
BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds
The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.Article d’analyse • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...Mise à jour du récit • Jun 16
BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations
Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.Mise à jour du récit • Jun 01
BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations
Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.Mise à jour du récit • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
Nouveau récit • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.Nouveau récit • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.Mise à jour du récit • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.Mise à jour du récit • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.Mise à jour du récit • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.Mise à jour du récit • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
Nouveau récit • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Mise à jour du récit • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.Mise à jour du récit • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.Mise à jour du récit • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.Mise à jour du récit • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.Mise à jour du récit • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.Mise à jour du récit • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.Rendement pour les actionnaires
| BSX | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 6.6% | 2.3% | 4.9% |
| 1Y | -53.2% | -12.8% | 21.3% |
Rendement vs Industrie: BSX a sous-performé le secteur US Medical Equipment qui a rapporté -12.8 % au cours de l'année écoulée.
Rendement vs marché: BSX a sous-performé le marché US qui a rapporté 21.3 % au cours de l'année écoulée.
Volatilité des prix
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: BSX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de BSX ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation développe, fabrique et commercialise des dispositifs médicaux destinés à être utilisés dans diverses spécialités médicales interventionnelles dans le monde entier. La société opère dans deux segments, MedSurg et Cardiovascular. Elle propose des dispositifs pour diagnostiquer et traiter une série d'affections gastro-intestinales, tels que des clips de résolution, des systèmes de stents biliaires, des stents et des systèmes d'électrocautérisation améliorés, SpyGlass, des scopes à usage unique utilisés pour les procédures diagnostiques et thérapeutiques dans le système pancréaticobiliaire, dans les procédures de cholangiopancréatographie rétrograde endoscopique, et des duodénoscopes à usage unique, ainsi que des produits de chirurgie endoluminale et de prévention des infections ; des dispositifs pour traiter les affections urologiques, notamment des stents urétraux, des cathéters, des paniers, des fils-guides, des dysfonctionnements urinaires et intestinaux, des gaines, des ballons, des urétéroscopes numériques flexibles à usage unique, des systèmes à laser holmium, des implants péniens, des sphincters urinaires artificiels, des systèmes à laser et des systèmes à hydrogel ; et des dispositifs pour traiter les troubles neurologiques du mouvement et gérer la douleur chronique, notamment des systèmes de stimulation de la moelle épinière, des systèmes d'ablation par radiofréquence, des systèmes d'ablation des nerfs intra-osseux et des systèmes de stimulation cérébrale profonde.
Boston Scientific Corporation Résumé des fondamentaux
| BSX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$70.19b |
| Bénéfices(TTM) | US$3.67b |
| Recettes(TTM) | US$21.00b |
19.4x
Ratio P/E3.4x
Ratio P/SLe site BSX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BSX compte de résultat (TTM) | |
|---|---|
| Recettes | US$21.00b |
| Coût des recettes | US$6.47b |
| Marge brute | US$14.53b |
| Autres dépenses | US$10.85b |
| Les revenus | US$3.67b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 2.54 |
| Marge brute | 69.19% |
| Marge bénéficiaire nette | 17.50% |
| Ratio dettes/capitaux propres | 49.7% |
Quelles ont été les performances à long terme de BSX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/04 11:50 |
| Cours de l'action en fin de journée | 2026/08/04 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Boston Scientific Corporation est couverte par 58 analystes. 29 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |